<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02509585</url>
  </required_header>
  <id_info>
    <org_study_id>NAV3-19</org_study_id>
    <nct_id>NCT02509585</nct_id>
  </id_info>
  <brief_title>A Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection</brief_title>
  <official_title>A Prospective, Open-Label Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardinal Health 414, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardinal Health 414, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, open-label, within-patient, multi-center study of Lymphoseek in the detection of
      lymph nodes in subjects with known cancer of the cervix. All subjects will receive a single
      dose of 50 µg Lymphoseek radiolabeled with 2 mCi (74 MBq) Tc 99m.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    low accrual
  </why_stopped>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Per-subject False Negative Rate</measure>
    <time_frame>1 day</time_frame>
    <description>Proportion of subjects with pathologically negative Lymphoseek-identified SLNs and at least one pathologically positive non-SLN</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Per-subject Sensitivity</measure>
    <time_frame>1 day</time_frame>
    <description>Proportion of subjects with at least one pathologically positive Lymphoseek-identified SLN that have at least one pathologically positive lymph node</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-subject Negative Predictive Value</measure>
    <time_frame>1 day</time_frame>
    <description>Proportion of subjects with pathologically negative Lymphoseek-identified SLN(s) with no pathologically positive lymph nodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-subject Accuracy</measure>
    <time_frame>1 day</time_frame>
    <description>Proportion of subjects accurately indentified by Lymphoseek</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Lymph Nodes Identified Intraoperatively by a Dye That Are Also Identified by Lymphoseek</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Lymph Nodes Per-subject Identified by Lymphoseek</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Lymph Nodes Per-subject Identified by Other Dyes</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-subject Concordance</measure>
    <time_frame>1 day</time_frame>
    <description>Subjects whose lymph nodes were determined to be dye positive that were also identified by Lymphoseek</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per-subject Reverse Concordance</measure>
    <time_frame>1 day</time_frame>
    <description>Number of subjects whose lymph nodes that were identified by Lymphoseek were also all identified by dye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Uterine Cervical Neoplasms</condition>
  <arm_group>
    <arm_group_label>Tc99m tilmanocept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mCi (74 MBq), 50 ug of Tc99M tilmanocept single administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tc99m tilmanocept</intervention_name>
    <description>A single dose of 2 mCi (74 MBq) and 50 ug of Tc99m tilmanocept administered peritumorally no more than 20 hours before surgery</description>
    <arm_group_label>Tc99m tilmanocept</arm_group_label>
    <other_name>Lymphoseek</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has provided written informed consent with HIPAA authorization

          -  Has cervical cancer and is a candidate for surgical intervention, with lymph node
             dissection being a part of the surgical plan.

          -  Is at least 18 years of age at the time of consent

          -  Has an ECOG performance status of Grade 0 to 2

          -  Has the following International Federation of Gynecology and Obstetrics (FIGO)
             IA2-IIA1staging. Subjects with a single enlarged/suspicious node on PET/CT will still
             be considered eligible as consistent with FIGO guidelines.

          -  If of childbearing potential, the subject has a negative pregnancy test within 48
             hours before administration of Lymphoseek, has been surgically sterilized, or has been
             postmenopausal for at least 1 year

        Exclusion Criteria:

          -  The subject has had preoperative chemotherapy, immunotherapy, or radiation therapy
             within the 30 days prior to Lymphoseek administration

          -  Has had previous surgery or radiation to node basins that would be involved in the ILM
             procedure

          -  Has a known allergy to dextran

          -  Is breast-feeding or pregnant

          -  Before the administration of Lymphoseek, has received any radiopharmaceutical within 7
             radioactive half-lives of that radiopharmaceutical

          -  Is scheduled for surgery and/or another invasive procedure other than the primary
             surgical intervention within the 3 days after Lymphoseek administration

          -  Has received an investigational product within the 30 days prior to Lymphoseek
             administration
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Blue, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cardinal Health 414, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>July 24, 2015</study_first_submitted>
  <study_first_submitted_qc>July 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2015</study_first_posted>
  <results_first_submitted>January 16, 2019</results_first_submitted>
  <results_first_submitted_qc>February 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 11, 2019</results_first_posted>
  <disposition_first_submitted>May 16, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>May 16, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 18, 2018</disposition_first_posted>
  <last_update_submitted>February 7, 2019</last_update_submitted>
  <last_update_submitted_qc>February 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 3, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT02509585/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tc99m Tilmanocept</title>
          <description>2 mCi (74 MBq), 50 ug of Tc99M tilmanocept single administration
Tc99m tilmanocept: A single dose of 2 mCi (74 MBq) and 50 ug of Tc99m tilmanocept administered peritumorally no more than 20 hours before surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tc99m Tilmanocept</title>
          <description>Enrolled subjects who were administered any injection of Tc99m tilmanocept.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.53" spread="7.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG Status</title>
          <description>Grade 0: Fully active (better outcome) Grade 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature Grade 2: Ambulatory and capable of all self-care but unable to carry out any work activities Grade 3: Capable of only limited self-care Grade 4: Completely disabled. Cannot carry on any self-care. Grade 5: Dead (worse outcome)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Per-subject False Negative Rate</title>
        <description>Proportion of subjects with pathologically negative Lymphoseek-identified SLNs and at least one pathologically positive non-SLN</description>
        <time_frame>1 day</time_frame>
        <population>Participants receiving a single dose of 50 µg Lymphoseek radiolabeled with 2 mCi (74 MBq) Tc 99m for whom at least one lymph node was removed with histopathology available</population>
        <group_list>
          <group group_id="O1">
            <title>Intent-To-Treat</title>
            <description>2 mCi (74 MBq), 50 ug of Tc99M tilmanocept single administration
Tc99m tilmanocept: A single dose of 2 mCi (74 MBq) and 50 ug of Tc99m tilmanocept administered peritumorally no more than 20 hours before surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Per-subject False Negative Rate</title>
          <description>Proportion of subjects with pathologically negative Lymphoseek-identified SLNs and at least one pathologically positive non-SLN</description>
          <population>Participants receiving a single dose of 50 µg Lymphoseek radiolabeled with 2 mCi (74 MBq) Tc 99m for whom at least one lymph node was removed with histopathology available</population>
          <units>Proportion of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".333" lower_limit=".0084" upper_limit=".9057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-subject Sensitivity</title>
        <description>Proportion of subjects with at least one pathologically positive Lymphoseek-identified SLN that have at least one pathologically positive lymph node</description>
        <time_frame>1 day</time_frame>
        <population>Participants receiving a single dose of 50 µg Lymphoseek radiolabeled with 2 mCi (74 MBq) Tc 99m for whom at least one lymph node was removed with histopathology available</population>
        <group_list>
          <group group_id="O1">
            <title>Intent-To-Treat</title>
            <description>2 mCi (74 MBq), 50 ug of Tc99M tilmanocept single administration
Tc99m tilmanocept: A single dose of 2 mCi (74 MBq) and 50 ug of Tc99m tilmanocept administered peritumorally no more than 20 hours before surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Per-subject Sensitivity</title>
          <description>Proportion of subjects with at least one pathologically positive Lymphoseek-identified SLN that have at least one pathologically positive lymph node</description>
          <population>Participants receiving a single dose of 50 µg Lymphoseek radiolabeled with 2 mCi (74 MBq) Tc 99m for whom at least one lymph node was removed with histopathology available</population>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".667" lower_limit=".0942" upper_limit=".9916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-subject Negative Predictive Value</title>
        <description>Proportion of subjects with pathologically negative Lymphoseek-identified SLN(s) with no pathologically positive lymph nodes</description>
        <time_frame>1 day</time_frame>
        <population>Participants receiving a single dose of 50 µg Lymphoseek radiolabeled with 2 mCi (74 MBq) Tc 99m for whom at least one lymph node was removed with histopathology available</population>
        <group_list>
          <group group_id="O1">
            <title>Intent-To-Treat</title>
            <description>2 mCi (74 MBq), 50 ug of Tc99M tilmanocept single administration
Tc99m tilmanocept: A single dose of 2 mCi (74 MBq) and 50 ug of Tc99m tilmanocept administered peritumorally no more than 20 hours before surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Per-subject Negative Predictive Value</title>
          <description>Proportion of subjects with pathologically negative Lymphoseek-identified SLN(s) with no pathologically positive lymph nodes</description>
          <population>Participants receiving a single dose of 50 µg Lymphoseek radiolabeled with 2 mCi (74 MBq) Tc 99m for whom at least one lymph node was removed with histopathology available</population>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".9375" lower_limit=".6977" upper_limit=".9984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-subject Accuracy</title>
        <description>Proportion of subjects accurately indentified by Lymphoseek</description>
        <time_frame>1 day</time_frame>
        <population>Participants receiving a single dose of 50 µg Lymphoseek radiolabeled with 2 mCi (74 MBq) Tc 99m for whom at least one lymph node was removed with histopathology available</population>
        <group_list>
          <group group_id="O1">
            <title>Intent-To-Treat</title>
            <description>2 mCi (74 MBq), 50 ug of Tc99M tilmanocept single administration
Tc99m tilmanocept: A single dose of 2 mCi (74 MBq) and 50 ug of Tc99m tilmanocept administered peritumorally no more than 20 hours before surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Per-subject Accuracy</title>
          <description>Proportion of subjects accurately indentified by Lymphoseek</description>
          <population>Participants receiving a single dose of 50 µg Lymphoseek radiolabeled with 2 mCi (74 MBq) Tc 99m for whom at least one lymph node was removed with histopathology available</population>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".9444" lower_limit=".7271" upper_limit=".9986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Lymph Nodes Identified Intraoperatively by a Dye That Are Also Identified by Lymphoseek</title>
        <time_frame>1 day</time_frame>
        <population>Participants receiving a single dose of 50 µg Lymphoseek radiolabeled with 2 mCi (74 MBq) Tc 99m for whom at least one lymph node was removed with histopathology available</population>
        <group_list>
          <group group_id="O1">
            <title>Intent-To-Treat</title>
            <description>2 mCi (74 MBq), 50 ug of Tc99M tilmanocept single administration
Tc99m tilmanocept: A single dose of 2 mCi (74 MBq) and 50 ug of Tc99m tilmanocept administered peritumorally no more than 20 hours before surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Lymph Nodes Identified Intraoperatively by a Dye That Are Also Identified by Lymphoseek</title>
          <population>Participants receiving a single dose of 50 µg Lymphoseek radiolabeled with 2 mCi (74 MBq) Tc 99m for whom at least one lymph node was removed with histopathology available</population>
          <units>Proportion of Condordant Nodes</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Dye Positive Nodes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Dye Positive Nodes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".8049" lower_limit=".6513" upper_limit=".9118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Lymph Nodes Per-subject Identified by Lymphoseek</title>
        <time_frame>1 day</time_frame>
        <population>Participants receiving a single dose of 50 µg Lymphoseek radiolabeled with 2 mCi (74 MBq) Tc 99m for whom at least one lymph node was removed with histopathology available</population>
        <group_list>
          <group group_id="O1">
            <title>Intent-To-Treat</title>
            <description>2 mCi (74 MBq), 50 ug of Tc99M tilmanocept single administration
Tc99m tilmanocept: A single dose of 2 mCi (74 MBq) and 50 ug of Tc99m tilmanocept administered peritumorally no more than 20 hours before surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Lymph Nodes Per-subject Identified by Lymphoseek</title>
          <population>Participants receiving a single dose of 50 µg Lymphoseek radiolabeled with 2 mCi (74 MBq) Tc 99m for whom at least one lymph node was removed with histopathology available</population>
          <units>Nodes Per Subject</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Total Lymph Nodes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Total Lymph Nodes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.72" lower_limit="2.09" upper_limit="3.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Lymph Nodes Per-subject Identified by Other Dyes</title>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intent-To-Treat</title>
            <description>2 mCi (74 MBq), 50 ug of Tc99M tilmanocept single administration
Tc99m tilmanocept: A single dose of 2 mCi (74 MBq) and 50 ug of Tc99m tilmanocept administered peritumorally no more than 20 hours before surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Lymph Nodes Per-subject Identified by Other Dyes</title>
          <units>Nodes Per Subject</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Total Lymph Nodes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Total Lymph Nodes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.41" lower_limit="1.64" upper_limit="3.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-subject Concordance</title>
        <description>Subjects whose lymph nodes were determined to be dye positive that were also identified by Lymphoseek</description>
        <time_frame>1 day</time_frame>
        <population>Participants receiving a single dose of 50 µg Lymphoseek radiolabeled with 2 mCi (74 MBq) Tc 99m for whom at least one lymph node was removed with histopathology available</population>
        <group_list>
          <group group_id="O1">
            <title>Intent-To-Treat</title>
            <description>2 mCi (74 MBq), 50 ug of Tc99M tilmanocept single administration
Tc99m tilmanocept: A single dose of 2 mCi (74 MBq) and 50 ug of Tc99m tilmanocept administered peritumorally no more than 20 hours before surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Per-subject Concordance</title>
          <description>Subjects whose lymph nodes were determined to be dye positive that were also identified by Lymphoseek</description>
          <population>Participants receiving a single dose of 50 µg Lymphoseek radiolabeled with 2 mCi (74 MBq) Tc 99m for whom at least one lymph node was removed with histopathology available</population>
          <units>Proportion of Condordant Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Dye Positive Nodes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Dye Positive Nodes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit=".7819" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Per-subject Reverse Concordance</title>
        <description>Number of subjects whose lymph nodes that were identified by Lymphoseek were also all identified by dye</description>
        <time_frame>1 day</time_frame>
        <population>Participants receiving a single dose of 50 µg Lymphoseek radiolabeled with 2 mCi (74 MBq) Tc 99m for whom at least one lymph node was removed with histopathology available</population>
        <group_list>
          <group group_id="O1">
            <title>Intent-To-Treat</title>
            <description>2 mCi (74 MBq), 50 ug of Tc99M tilmanocept single administration
Tc99m tilmanocept: A single dose of 2 mCi (74 MBq) and 50 ug of Tc99m tilmanocept administered peritumorally no more than 20 hours before surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Per-subject Reverse Concordance</title>
          <description>Number of subjects whose lymph nodes that were identified by Lymphoseek were also all identified by dye</description>
          <population>Participants receiving a single dose of 50 µg Lymphoseek radiolabeled with 2 mCi (74 MBq) Tc 99m for whom at least one lymph node was removed with histopathology available</population>
          <units>Proportion of Reverse Condordant Subj.</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Hot Positive Nodes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Hot Positive Nodes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".8333" lower_limit=".5858" upper_limit=".9642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events</title>
        <time_frame>7 days</time_frame>
        <population>Enrolled subjects who were administered any injection of Tc99m tilmanocept.</population>
        <group_list>
          <group group_id="O1">
            <title>Tc99m Tilmanocept</title>
            <description>Enrolled patients who were administered any injection of Lymphoseek.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events</title>
          <population>Enrolled subjects who were administered any injection of Tc99m tilmanocept.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day of injection through 24 hours post injection</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tc99m Tilmanocept</title>
          <description>Enrolled subjects who were administered any injection of Tc99m tilmanocept.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Not related to Lymphoseek.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Small amount of bleeding at 3:00 injection site</sub_title>
                <description>Not related to Lymphoseek.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in right arm</sub_title>
                <description>Not related to Lymphoseek.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Not related to Lymphoseek.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal bleeding</sub_title>
                <description>Not related to Lymphoseek.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI shall not submit a publication to journals or professional societies without the prior written approval of the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>LaTosha Eligon</name_or_title>
      <organization>Cardinal Health</organization>
      <phone>913-661-3896</phone>
      <email>latosha.eligon@cardinalhealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

